Imvax is a clinical-stage biotechnology company that specializes in developing personalized, whole tumor-derived immunotherapies. With their revolutionary Goldspire TM Platform, Imvax is able to capture the complete antigen signature of a tumor, using it to trigger the patient's natural immune response against any remaining cancer cells. Their cutting-edge approach harnesses decades of research and utilizes validated technologies to create personalized treatments.

Imvax's pipeline showcases promising clinical data in Glioblastoma, as well as preclinical data in various other solid tumors. This diverse pipeline highlights their commitment to developing effective and tailored treatments for different types of cancer. Furthermore, Imvax has garnered recognition for their groundbreaking work, with recent publications and presentations demonstrating the clinical relevance and effectiveness of their lead program, IGV-001, in Glioblastoma.

Based in Philadelphia, Imvax is driven by a team of dedicated professionals who are passionate about making a difference in the lives of patients and their families. Through their innovative research and commitment to personalized medicine, Imvax is revolutionizing cancer treatment